- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02746341
Natural History Study of Patients With MPS IIIA
August 30, 2021 updated by: LYSOGENE
An Observational, Prospective, Multi-center, Natural History Study of Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
Evaluate the clinical progression in patients with MPS IIIA who are untreated with any investigational product and to obtain standardized assessments: neurocognitive, behavioral, sleep-wake habits and effect of MPS IIIA on the quality of life of patients and their families.
Study Overview
Status
Completed
Conditions
Detailed Description
This is a multicenter, multinational, longitudinal, observational study in children aged up to and including 9 years, who have been diagnosed with MPS IIIA.
The study will detail the natural course of MPS IIIA via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
This information is anticipated to inform the design and interpretation of future interventional studies.
Study Type
Observational
Enrollment (Actual)
23
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Porto Alegre, Brazil, 90035-003
- Hospital de Clinicas de Porto Alegre
-
-
-
-
-
Paris, France
- Armand Trousseau Public Hospital
-
-
-
-
-
Hamburg, Germany
- University Medical Center Hamburg-Eppendorf
-
-
-
-
-
Amsterdam, Netherlands
- Academic Medical Center, Emma Children's Hospital
-
-
-
-
-
London, United Kingdom
- Great Ormond Street Hospital NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 second to 9 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects diagnosed with MPS IIIA
Description
Inclusion Criteria:
- Documented MPS IIIA diagnosis
- Children up to and including 9 years of age
- The patient is sufficiently able, in the opinion of the Investigator, to adhere to the study visit schedule and other protocol requirements
- The patient's parent(s) or legal guardian(s) has signed written informed consent, according to the local regulations and after all relevant aspects of the -study have been explained and discussed
Exclusion Criteria:
- The patient is participating in a clinical trial of any potential disease-modifying investigational medicinal product or taking high dose (>100 mg/kg/day) synthetic genistein (patients on low dose or naturally derived genistein can be included in this study).
- The patient has received a hematopoietic stem cell or bone marrow transplant or gene therapy.
- The patient has received enzyme replacement therapy in the last 6 months.
- Homozygous or compound heterozygous for the S298P mutation or the investigator and/or trial steering committee considers the patient not to have the classical severe form of MPS IIIA.
- Individuals with rare and unrelated serious comorbidities e.g. Down syndrome, intraventricular hemorrhage in the new-born period, or extreme low birth weight (<1500 grams).
- Visual or hearing impairment sufficient, in the clinical judgment of the investigator, to preclude cooperation with neurodevelopmental testing. Use of hearing aids is permitted.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change from baseline in cognitive function using the Bayley scales of infant and toddler development third edition
Time Frame: Baseline, and every 6 months, for up to 24 months
|
Baseline, and every 6 months, for up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in the adaptive behavior composite standard score as measured by the Vineland Adaptive Behavior scale
Time Frame: Baseline and every 6 months up to 24 months
|
Baseline and every 6 months up to 24 months
|
Sleep disturbances measured by Actigraphy
Time Frame: Baseline and every 3 months up to 24 months
|
Baseline and every 3 months up to 24 months
|
Patient Quality of Life Questionnaires
Time Frame: Baseline and every 6 months up to 24 months
|
Baseline and every 6 months up to 24 months
|
Change from baseline in total cortical grey matter volume
Time Frame: Baseline, 12 months, 24 months
|
Baseline, 12 months, 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Actual)
May 1, 2019
Study Completion (Actual)
May 1, 2019
Study Registration Dates
First Submitted
April 15, 2016
First Submitted That Met QC Criteria
April 18, 2016
First Posted (Estimate)
April 21, 2016
Study Record Updates
Last Update Posted (Actual)
August 31, 2021
Last Update Submitted That Met QC Criteria
August 30, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P3-LYS-SAF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidosis IIIA
-
JCR Pharmaceuticals Co., Ltd.RecruitingMucopolysaccharidosis III-AGermany
-
Nationwide Children's HospitalSanfilippo Children's Research Foundation; The Sanfilippo Research Foundation; The Children's Medical Research FoundationCompletedMucopolysaccharidosis Type IIIA | Mucopolysaccharidosis Type IIIBUnited States
-
Sanguine BiosciencesDenali Therapeutics Inc.RecruitingMucopolysaccharidosis III-AUnited States
-
ShireCompletedMucopolysaccharidosis (MPS)United Kingdom, Netherlands
-
University of ManchesterUniversity College, London; Manchester University NHS Foundation Trust; Orchard... and other collaboratorsActive, not recruitingMucopolysaccharidosis Type IIIAUnited Kingdom
-
LYSOGENEActive, not recruitingMucopolysaccharidosis Type IIIAGermany, United States, United Kingdom, France, Netherlands
-
Denali Therapeutics Inc.RecruitingMucopolysaccharidosis Type IIIAUnited States
-
Ultragenyx Pharmaceutical IncAbeona Therapeutics, IncTerminatedMucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo AUnited States, Spain, Australia
-
Ultragenyx Pharmaceutical IncAbeona Therapeutics, IncActive, not recruitingMucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo AUnited States, Australia, Spain
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VIIUnited States, Canada